Free Trial

agilon health (AGL) Stock Forecast & Price Target

agilon health logo
$1.71 +0.04 (+2.40%)
(As of 09:45 AM ET)

agilon health - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
3
Hold
15
Buy
2

Based on 20 Wall Street analysts who have issued ratings for agilon health in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 20 analysts, 3 have given a sell rating, 15 have given a hold rating, and 2 have given a buy rating for AGL.

Consensus Price Target

$6.05
253.80% Upside
According to the 20 analysts' twelve-month price targets for agilon health, the average price target is $6.05. The highest price target for AGL is $18.00, while the lowest price target for AGL is $1.75. The average price target represents a forecasted upside of 253.80% from the current price of $1.71.
Get the Latest News and Ratings for AGL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for agilon health and its competitors.

Sign Up

AGL Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
8 Buy rating(s)
Hold
15 Hold rating(s)
14 Hold rating(s)
14 Hold rating(s)
1 Hold rating(s)
Sell
3 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$6.05$8.03$8.57$22.50
Forecasted Upside253.80% Upside185.30% Upside91.65% Upside90.52% Upside
Consensus Rating
Reduce
Hold
Hold
Moderate Buy

AGL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AGL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

agilon health Stock vs. The Competition

Typeagilon healthMedical CompaniesS&P 500
Consensus Rating Score
1.95
2.80
2.50
Consensus RatingReduceModerate BuyModerate Buy
Predicted Upside260.12% Upside26,931.47% Upside9.83% Upside
News Sentiment Rating
Neutral News

See Recent AGL News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/19/2024Royal Bank of Canada
4 of 5 stars
 Reiterated RatingOutperform ➝ Outperform$3.00 ➝ $3.00+86.92%
11/13/2024Citigroup
3 of 5 stars
D. Grosslight
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetSell ➝ Sell$2.50 ➝ $1.75-5.41%
11/12/2024Stifel Nicolaus
4 of 5 stars
 Lower TargetHold ➝ Hold$7.00 ➝ $2.00+6.95%
11/11/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$6.00 ➝ $2.00-1.96%
11/11/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight ➝ Underweight$5.00 ➝ $2.00+7.53%
11/11/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Davides
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
11/8/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Daniels
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
10/8/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetIn-Line ➝ In-Line$7.00 ➝ $4.00+25.79%
10/2/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Underperform$3.00-14.53%
8/9/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$5.00 ➝ $4.00-27.67%
8/8/2024Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00+57.89%
5/30/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/30/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$6.00+4.08%
5/24/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$6.40 ➝ $6.50+15.15%
2/26/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold$25.00 ➝ $6.50+3.67%
1/8/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
W. Mayo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
1/8/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
1/8/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Peer Perform
1/5/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral$17.00 ➝ $9.00+12.36%
12/11/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$14.00+21.21%
11/13/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$23.00 ➝ $16.00+47.47%
3/6/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$21.00 ➝ $30.00+18.95%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 10:07 AM ET.


AGL Forecast - Frequently Asked Questions

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for agilon health is $6.05, with a high forecast of $18.00 and a low forecast of $1.75.

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for agilon health in the last twelve months. There are currently 3 sell ratings, 15 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" AGL shares.

According to analysts, agilon health's stock has a predicted upside of 253.80% based on their 12-month stock forecasts.

Over the previous 90 days, agilon health's stock had 3 downgrades by analysts.

agilon health has been rated by research analysts at Bank of America, Barclays, Citigroup, Evercore ISI, JMP Securities, Royal Bank of Canada, Stifel Nicolaus, TD Cowen, and William Blair in the past 90 days.

Analysts like agilon health less than other "medical" companies. The consensus rating for agilon health is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AGL compares to other companies.


This page (NYSE:AGL) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners